Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 56 |
| Active Pipeline (Recruiting Now) | 16 (9) |
| Completed vs Stopped Early | 5 / 4 (7.1%) |
| Median Closed Actual Enrollment | 33 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Beijing Cancer Hospital | Beijing, Beijing Municipality | 17 |
| Peking University Cancer Hospital | Beijing | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07127822 | Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Peking University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.